210 related articles for article (PubMed ID: 34515190)
1. Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience.
Karivedu V; Bonomi M; Issa M; Blakaj A; Klamer BG; Pan X; Old M; Bhateja P; Kang S; Seim N; Ozer E; Agrawal A; Mitchell D; Gamez ME; Grecula J; Jhawar SR; Baliga S; Carrau RL; Rocco J; Blakaj D
Oncol Res Treat; 2021; 44(10):521-529. PubMed ID: 34515190
[TBL] [Abstract][Full Text] [Related]
2. A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN).
Grover S; Mitra N; Wan F; Lukens JN; Sharma S; Bauman J; Masroor F; Cohen RB; Desai A; Algazy K; Alonso-Basanta M; Ahn P; Kevin Teo BK; Chalian AA; Weinstein GS; O'Malley BW; Lin A
Am J Clin Oncol; 2016 Oct; 39(5):522-7. PubMed ID: 27441910
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
4. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation.
Rühle A; Weymann M; Behrens M; Marschner S; Haderlein M; Fabian A; Senger C; Dickstein DR; Kraft J; von der Grün J; Chen E; Aquino-Michaels T; Domschikowski J; Bickel A; Altay-Langguth A; Kalinauskaite G; Lewitzki V; Bonomi M; Blakaj DM; Jhawar SR; Baliga S; Barve R; Ferentinos K; Zamboglou C; Schnellhardt S; Haehl E; Spohn SKB; Kuhnt T; Zöller D; Guckenberger M; Budach V; Belka C; Bakst R; Mayer A; Schmidberger H; Grosu AL; Balermpas P; Stromberger C; Nicolay NH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1282-1293. PubMed ID: 37914144
[TBL] [Abstract][Full Text] [Related]
6. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.
Han J; Zakeri K; Raab G; Hesse J; Shamseddine A; Chen L; Yu Y; Kang JJ; McBride SM; Riaz N; Tsai CJ; Gelblum D; Sherman EJ; Wong RJ; Michel L; Lee NY
Head Neck; 2023 Sep; 45(9):2207-2216. PubMed ID: 37439286
[TBL] [Abstract][Full Text] [Related]
7. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
12. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer.
Alamgeer M; Coleman A; McDowell L; Giddings C; Safdar A; Sigston E; Wang Y; Subramaniam A
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1674. PubMed ID: 35792145
[TBL] [Abstract][Full Text] [Related]
15. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
19. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
[TBL] [Abstract][Full Text] [Related]
20. Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
Xiang M; Colevas AD; Holsinger FC; Le QX; Beadle BM
J Natl Compr Canc Netw; 2019 Sep; 17(9):1065-1073. PubMed ID: 31487677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
